What SEC filings does FibroBiologics, Inc. submit to the SEC?

FibroBiologics, Inc. (FBLG) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about FBLG?

A Form 4 for FBLG discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from FibroBiologics, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for FBLG?

The 10-K is FibroBiologics, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all FBLG SEC filings directly on EDGAR?

You can view all historical FibroBiologics, Inc. filings on the SEC EDGAR company page for FBLG. Each filing card on this page links directly to the original SEC document.

How often does FibroBiologics, Inc. file with the SEC?

FibroBiologics, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling FBLG shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

FBLG SEC Filing News — FibroBiologics, Inc.

Latest SEC filings for FibroBiologics, Inc. (FBLG) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-08.

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It al…

Sector: Healthcare Industry: Biotechnology Market Cap: $6.8M CIK: 1958777

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

What you're looking at: Each item below is parsed from an actual SEC filing submitted by FibroBiologics, Inc.. Form 4 = confirmed insider transaction · Form 144 = proposed sale notice · 8-K = material event (earnings, M&A, leadership change, etc.) · 10-Q / 10-K = quarterly / annual report.

FBLG Filing Activity Snapshot 2026-05-04 — 2026-10-08

Insider Transactions (Form 4)

0 buys vs 0 sells

Insider buying and selling activity is balanced in this period.

Insider Transactions 9 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 9 filings in this group are Form 4s for FibroBiologics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 9 insider filings shown, the breakdown is 9 compensation award. None of the classified filings involved a discretionary open-market trade, so this period says nothing about what insiders think of the price.

What each transaction type means

Compensation award ×9: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Form 4 Compensation award Tax / Compensation Filing 2026-09-15

FBLG insider Form 4 filed for equity award, exercise, or tax withholding

Khoja Hamid (Chief Scientific Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	298,508	$1.68	$500.0K
`A`	Compensation award derivative · Warrant (Right to Buy)	298,508	—	—

Filing: Form 4 (Insider Transaction) Insider: Khoja Hamid (Chief Scientific Officer) Shares: 298,508

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

FBLG insider Form 4 filed for equity award, exercise, or tax withholding

Hoffman Robert E. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	30,803	—	—

Filing: Form 4 (Insider Transaction) Insider: Hoffman Robert E. (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

FBLG insider Form 4 filed for equity award, exercise, or tax withholding

Cilento Richard C. Jr. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	30,803	—	—

Filing: Form 4 (Insider Transaction) Insider: Cilento Richard C. Jr. (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

FBLG insider Form 4 filed for equity award, exercise, or tax withholding

Link Matthew (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	30,803	—	—

Filing: Form 4 (Insider Transaction) Insider: Link Matthew (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

FBLG insider Form 4 filed for equity award, exercise, or tax withholding

Niklas Victoria Ninon Olivia (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	30,803	—	—

Filing: Form 4 (Insider Transaction) Insider: Niklas Victoria Ninon Olivia (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-04

FBLG insider Form 4 filed for equity award, exercise, or tax withholding

O'HEERON PETE (Director, CHIEF EXECUTIVE OFFICER) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	92,410	—	—

Filing: Form 4 (Insider Transaction) Insider: O'HEERON PETE (Director, CHIEF EXECUTIVE OFFICER)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-04

FBLG insider Form 4 filed for equity award, exercise, or tax withholding

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	61,607	—	—

Filing: Form 4 (Insider Transaction) Insider: Khoja Hamid (Chief Scientific Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-04

FBLG insider Form 4 filed for equity award, exercise, or tax withholding

Davis Jason (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	61,607	—	—

Filing: Form 4 (Insider Transaction) Insider: Davis Jason (Chief Financial Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-04

FBLG insider Form 4 filed for equity award, exercise, or tax withholding

GARCIA RUBEN A (General Counsel) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	61,607	—	—

Filing: Form 4 (Insider Transaction) Insider: GARCIA RUBEN A (General Counsel)

View on SEC EDGAR → Open Filing Document →

Material Events 10 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 10 in this period for FibroBiologics, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-08